| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001214961 |
| P356 | DOI | 10.1186/1479-5876-7-101 |
| P932 | PMC publication ID | 2789051 |
| P698 | PubMed publication ID | 19943950 |
| P5875 | ResearchGate publication ID | 40037103 |
| P50 | author | Mariangela Figini | Q40493425 |
| Lucia Lopalco | Q43112481 | ||
| Barbara Frigerio | Q43260777 | ||
| P2093 | author name string | Luca Mollica | |
| Paolo Lusso | |||
| Samuele E Burastero | |||
| P2860 | cites work | Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults | Q24645675 |
| Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection | Q24795912 | ||
| HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells | Q24802813 | ||
| Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cells | Q24807250 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Cyclosporin A sensitivity of the HIV-1 long terminal repeat identifies distinct p56lck-dependent pathways activated by CD4 triggering | Q28290571 | ||
| CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization | Q28646881 | ||
| Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies | Q33384065 | ||
| The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation--data on four cases and review of the literature. | Q33494225 | ||
| Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. | Q33640055 | ||
| gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants | Q33782866 | ||
| Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains | Q33788810 | ||
| Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1. | Q33854440 | ||
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study | Q34269641 | ||
| Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen | Q34685578 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). | Q35585238 | ||
| Autoimmunity, anergy, lentiviral immunity and disease | Q35952048 | ||
| Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies | Q36229742 | ||
| The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure | Q36231657 | ||
| Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding | Q36353645 | ||
| The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules | Q36377062 | ||
| Biological therapies directed against cells in autoimmune disease | Q36494222 | ||
| In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. | Q36529013 | ||
| Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. | Q36635175 | ||
| Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys | Q36667267 | ||
| Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? | Q36765448 | ||
| HIV-1 and the self-nonself connection: how to sleep with the enemy and be much better off. | Q37280626 | ||
| High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination | Q37471315 | ||
| Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex | Q39593524 | ||
| Major CD4 epitopes involved in anti-CD4 T-cell autoimmunity in HIV-1 patients | Q40242577 | ||
| Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | Q40682865 | ||
| Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody | Q40752113 | ||
| Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells | Q40770881 | ||
| Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production | Q41069948 | ||
| Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience | Q41206002 | ||
| Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion | Q41606072 | ||
| NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells | Q41721893 | ||
| Induction of classical transplantation tolerance in the adult | Q41965507 | ||
| Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. A possible influence of paratope specificity on the mode of antigen processing | Q42153729 | ||
| Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients | Q42635758 | ||
| HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing | Q42942993 | ||
| Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens | Q43112410 | ||
| Induction of tolerance by monoclonal antibody therapy | Q43419298 | ||
| Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes | Q45052086 | ||
| Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. | Q45522873 | ||
| Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects | Q45759188 | ||
| Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors | Q45764498 | ||
| Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection | Q45853401 | ||
| Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia | Q48023288 | ||
| HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. | Q52004257 | ||
| CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. | Q52523164 | ||
| Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. | Q52843039 | ||
| HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. | Q52848179 | ||
| Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. | Q53515355 | ||
| Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study | Q58292015 | ||
| Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals | Q58292289 | ||
| Preincubation with anti-CD4 influences activation of human T cells by subsequent co-cross-linking of CD4 with CD3 | Q63859664 | ||
| Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules | Q67233696 | ||
| Anti-CD4 monoclonal antibody therapy in severe psoriasis | Q67544549 | ||
| Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation | Q67677171 | ||
| Anti-CD4 antibodies are associated with HIV-1 seroconversion and may be detectable before anti-HIV-1 antibodies. The Multicenter AIDS Cohort Study | Q67996567 | ||
| Stimulation and proliferation of CD4+ peripheral blood T lymphocytes induced by an anti-CD4 monoclonal antibody | Q68092456 | ||
| Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody | Q68326745 | ||
| Induction of immune tolerance by administration of monoclonal antibody to L3T4 | Q70299676 | ||
| Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A | Q71020302 | ||
| HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex | Q72095615 | ||
| Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients | Q72356869 | ||
| Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts | Q72680824 | ||
| Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4 | Q73420623 | ||
| Characterization of new monoclonal antibodies that discriminate between soluble and membrane CD4 and compete with human anti-CD4 autoimmune sera | Q73874162 | ||
| Autoimmune T-cell response to the CD4 molecule in HIV-infected patients | Q74545302 | ||
| T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients--an extended open trial | Q81497493 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CD4 molecule | Q412587 |
| autoantibody | Q785022 | ||
| human immunodeficiency virus infectious disease | Q18556697 | ||
| HIV type 1 | Q18907320 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 101 | |
| P577 | publication date | 2009-11-28 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection | |
| P478 | volume | 7 |
| Q30355763 | Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies |
| Q33983104 | Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4. |
| Q38222751 | Epitopes for Protective Immunity Targeting Antigens of Pathogen and/or Host (EPITAPH): Towards Novel Vaccines Against HIV and Other Medically Challenging Infections |
Search more.